Human corneas were received from the National Disease Research Institute Interchange (Philadelphia, PA) within 4 days of enucleation and were obtained in accordance with the guidelines of the Declaration of Helsinki for research involving human tissue. After the endothelial cell layers were removed from the cornea with forceps, the corneas were washed repeatedly in keratinocyte serum-free medium (K-SFM; Invitrogen-Gibco, Grand Island, NY) with supplements (25 mg bovine pituitary extract and 2.5 μg human recombinant EGF; Invitrogen-Gibco) and incubated concave side down overnight in 0.5 mL grade II Dispase (25 U/mL; Roche, Indianapolis, IN) at 4° C. After incubation, the epithelial layer was removed with forceps, and the stromal layer was cut into small pieces and incubated in 3 mL K-SFM plus supplements and 1000 U/mL type II collagenase for a minimum of 20 minutes and a maximum of 2 hours. At this time, the tissue was seeded into a 75-cm2 tissue culture flask in 3 mL Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen-Gibco) containing 20% fetal bovine serum, 1× antibiotic-antimycotic (Invitrogen-Gibco), 10 mM HEPES, 1.5% sodium bicarbonate (Invitrogen-Gibco), 0.004 N sodium hydroxide, and 0.2 μg/mL kanamycin (Sigma-Aldrich, St. Louis, MO). Once the cells reached confluence, they were harvested and seeded into 25-cm2 flasks in DMEM containing 10% fetal bovine serum. At 80% confluence, the medium was then replaced daily with SFM (Opti-MEM I; Invitrogen-Gibco) supplemented with 5 μg/mL gentamicin (Invitrogen-Gibco).
After 3 days, the medium was replaced with 2.0 mL SFM containing selected concentrations of either human recombinant interleukin (IL)-1α (R&D Systems, Inc., Minneapolis, MN), human recombinant tumor necrosis factor (TNF)-α (Genzyme, Cambridge, MA), or human recombinant IFN-γ (PBL Biomedical Laboratories, New Brunswick, NJ). Supernatants were then collected from cultures at selected times after stimulation and analyzed for human IP-10, MIG, and I-TAC with ELISA kits (R&D Systems, Inc.). Synergy was determined by treating the HCKs with select combinations of TNF-α and IFN-γ or IL-1α, and IFN-γ and comparing the results with single cytokine treatment. Minimum levels of detection were as follows: hIP-10, 1.67 pg/mL; hMIG, 3.84 pg/mL; and hI-TAC, 13.9 pg/mL). Results were read on a microplate reader (MRX; Dynatech Laboratories, Chantilly, VA) at 450 and 550 nm. A small paired t-test was used to calculate significant differences between chemokine levels.